Phase 2 Study of the efficacy and safety of erdafitinib in patients (pt) with bacillus Calmetter-Guerin (BCG)-unresponsive, high risk non-muscle invasive bladder cancer (HR-NMIBC) with FRFR3/2 alterations (alt) in THOR-2:cohort 2 interin analysis results

James W.F. Catto, Ben Tran, Viraj A. Master, Morgan Roupret, Geraldine Pignot, Andrea Tubaro, Nobuaki Shimizu, Nikhil Vasdev, Jurgen Gschwend, Yohann Loriot, Hiyoyuki Nishiyama, Joan Redorta, Siamak Daneshmand, Yuji Miura, Vahid Naini, Lauren Crow, Spyros Triantos, Mahadi Baig, Gary D. Steinberg

Research output: Contribution to journalArticle

Original languageEnglish
JournalLancet Oncology
Publication statusIn preparation - 11 Oct 2022

Cite this